Sleep Number is a stock in freefall — a Q1 earnings miss of historic proportions just knocked the stock down 22% in a single session to $1.90, and short sellers were already loaded up before the print.
The earnings shock defines this week. Sleep Number reported a Q1 loss of $2.19 per diluted share, compared to a $0.38 loss a year ago — a miss of roughly $1.85 against consensus. Revenue beat estimates, but the bottom line deteriorated sharply. UBS analyst Dan Silverstein responded immediately, cutting his price target from $4.00 to $2.00 while holding a Neutral rating. That target is now barely above where the stock closed Tuesday. Piper Sandler had already moved in the same direction in March, trimming their target from $12 to $5. Every analyst covering the name has been in continuous downgrade mode for over a year, and none carry a Buy.
Short interest was deeply entrenched heading into the print. At 28.7% of the free float — over 6.5 million shares — shorts controlled more than a quarter of the available stock. That position built by roughly 12% over the past month. The borrow market tells an even starker story: availability has collapsed to just 1.75% of outstanding short interest, meaning for every share still available to borrow, more than 56 are already out on loan. The lending pool was at 100% capacity for four consecutive sessions last week before nudging down marginally on Tuesday. Cost to borrow, now running near 8%, has jumped nearly five-fold from its level six weeks ago, when it sat below 1.6% — a sign of intensifying demand for short exposure across that entire period.
Options positioning reinforces the bearish lean. The put/call ratio has climbed to 1.24, well above its 20-day average of 0.72 and within a hair of its 52-week high of 1.55. That represents roughly 1.55 standard deviations of excess put demand versus recent norms — defensive positioning that accelerated through the past two weeks as the market braced for the Q1 release. The ORTEX short score of 71.6 out of 100 ranks in the bottom 6th percentile of the broader universe for short-side pressure.
The ownership picture adds context. Pacific Ridge Capital Partners added over 620,000 shares in Q1 2026, bringing its stake to 7.7% of shares outstanding — one of the few significant buyers in the institutional register. The top holder, Stadium Capital, has held steady at 11.4%. Against that backdrop, the last notable insider activity was a cluster of small-scale executive sales in March at $3.45 — a price now 45% above where the stock trades today. Acting CFO Robert Ryder did buy roughly 15,000 shares in early August 2025 at prices between $6.61 and $7.04, but the stock has since lost more than 70% of its value from those levels.
The next earnings event on the calendar is flagged for May 21. With the Q1 print now digested, attention turns to what Sleep Number says about the path toward profitability — and whether the cost structure deterioration visible in the $2.19 per share loss is structural or transient. With availability this tight and the ORTEX short score anchored in the low 70s for two straight weeks, the borrow dynamics rather than any fresh bearish catalyst will be the key variable to watch.
See the live data behind this article on ORTEX.
Open SNBR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
